Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
HRSA AIDS Drug Assistance Program Data Report Extension Request
The Health Resources and Services Administration (HRSA) is seeking public comment on extending OMB Control No. 0915-0345 for the AIDS Drug Assistance Program (ADAP) Data Report. The comment period closes on May 13, 2026. This is an administrative information collection extension request for an existing data reporting mechanism used to monitor ADAP program activities.
Determination That BILTRICIDE (Praziquantel) 600mg Tablet Was Not Withdrawn From Sale
The FDA has issued a determination that BILTRICIDE (Praziquantel) oral tablet, 600 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. This determination affects pharmaceutical manufacturers, healthcare providers, and patients who rely on this anti-parasitic medication. The notice confirms the drug remains available on the market and was not subject to removal due to regulatory safety concerns.
HRSA Extends Funding to University of Utah for Emergency Medical Services for Children Data Center
The Health Resources and Services Administration (HRSA) has issued a Notice extending funding to the University of Utah for the Emergency Medical Services for Children Data Center (EDC). The document, published in the Federal Register on April 13, 2026, is designated as Notice document number 2026-07035, appearing at citation 91 FR 18867.
GB18 Injection Phase I Tumor Cachexia Trial
The National Library of Medicine registered a Phase I clinical trial (NCT07519564) evaluating GB18 Injection in approximately 24 adults with tumor cachexia. The single-center, non-randomized study will assess safety, tolerability, and pharmacokinetics with an estimated completion date of December 2025. Healthcare providers and patients seeking experimental treatment options for cancer-related muscle wasting may reference this trial for enrollment eligibility. Sponsors conducting similar cachexia research should ensure their studies are similarly registered to maintain transparency and regulatory compliance.
Sexual Health, Metastatic Breast Cancer, Dana-Farber Study
A clinical trial sponsored by Dana-Farber Cancer Institute has been registered on ClinicalTrials.gov (NCT07519200). The study examines sexual health interventions in patients with metastatic breast cancer.
Metformin IPF Clinical Trial Study NCT07520110
The National Institutes of Health's ClinicalTrials.gov registry has registered a new interventional clinical trial (NCT07520110) titled 'Metformin IPF Clinical Trial Study.' The trial is investigating metformin as a potential treatment for idiopathic pulmonary fibrosis (IPF). No regulatory obligations, compliance deadlines, or penalties are associated with this registry listing.
Mindfulness-Based Stress Reduction for PTSD Road Traffic Victims
The National Library of Medicine registered clinical trial NCT07521020, a randomized controlled trial evaluating Mindfulness-Based Stress Reduction (MBSR) as an intervention for post-traumatic stress disorder in road traffic accident survivors. The study is sponsored by a healthcare institution and will assess PTSD symptom severity and quality of life outcomes.
Phase II Breast Cancer Trial, HER2-Negative, Sun Yat-sen University
Phase II Breast Cancer Trial, HER2-Negative, Sun Yat-sen University
Methods for Transgenerational Genome Editing in Plants
The USPTO published patent application US20260098272A1 for methods of transgenerational genome editing in plants. The application discloses nucleic acid constructs encoding RNA-guided nucleases under constitutive promoters combined with guide RNAs for editing plant genomes across generations. Inventors include Giane Balser, Lisa Kanizay, Ramanjot Kaur, Thomas Scott Ream, Zarir Vaghchhipawala, and Chenxi Wu. The application was filed on October 6, 2025, under application number 19350752.
Method for Increasing Recombinant Protein Expression
The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
720 changes in last 7 days
Latest high priority updates
141 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.